Global Bispecific Antibody Market Opportunity To Surpass USD 8 Billion By 2025

” Global Bispecific Antibody Market, Drug Sales  and Clinical Pipeline Insight 2025″ Report Highlights:

• Applications of Bispecific Antibodies

• Global Bispecific Antibody Market Overview: Drug and Market Sales

• Global Bispecific Antibody Market Opportunity: US$  8 Billion by 2025

• US and Japan Market Share Opportunity:  Greater Than 40% by 2025

• Bispecific Antibody Clinical Pipeline: 224 Drugs

• Commercially Available Bispecific Antibody: 2 (HEMLIBRA and  Blincyto)

Download Report:    https://www.kuickresearch.com/report-global-bispecific-antibody-market,-drug-sales–and-clinical-pipeline-insight-2025.php

or Contact: neeraj@kuickresearch.com

 

1. History of Monoclonal Antibodies

2. Overview of Bispecific Monoclonal Antibody

3. Mechanism Of Action Of Bispecific Antibody

  3.1 Trifunctional Antibody: Catumaxomab (Removabandreg;)

  3.2 Blinatumomab

4. The Design and Engineering of IgG like Bispecific Antibodies

  4.1 Quadroma (Hybrid Hydromas) Approach

  4.2 “Knobs Into Holes” Approach

  4.3 CrossMab Approach

  4.4 Dual-Variable-Domain Immunoglobulin Approach

5. The Design and Engineering of Small Bispecific Antibodies

  5.1 Bispecific Diabodies

  5.2 Bispecific T-Cell Engager Antibodies (BiTEs)

6. Advantage of Bispecific Antibodies upon Monospecific Monoclonal Antibodies

7. Applications of Bispecific Antibodies

  7.1 BsMAb for Diagnosis of Infectious Diseases

    7.1.1 Diagnosis of Bacterial Infections

    7.1.2 Diagnosis of Viral Infections

  7.2 BsMAb for Cancer Diagnostic

  7.3 BsAbs Blocking Signaling Pathways

  7.4 BsAbs Targeting Tumor Angiogenesis

  7.5 Specific Delivery of Effector Compounds to Targets

  7.6 Bispecific Antibodies and Gene Therapy

8. Global Bispecific Antibody Market Overview

  8.1 Current Market Scenario

    8.1.1 Catumaxomab (Removab)

    8.1.2 Blinatumomab

    8.1.3 Duligotumab

    8.1.4 SAR 156597

  8.2 Global Bispecific Antibodies Clinical Pipeline Overview

9. Global Bispecific Antibody Market Dynamics

  9.1 Favorable Market Parameters

    9.1.1 Target Patient Base

    9.1.2 Severity Of The Disease

    9.1.3 Unavailability Of Completely Curing Drugs

    9.1.4 Side Effects of the Existing Drugs

    9.1.5 Specificity of Monoclonal Antibodies in Targeting Cancer Cells

  9.2 Commercialization Challenges

    9.2.1 Stringent Regulatory Guidelines

    9.2.2 Long Duration of Research and Development

    9.2.3 Clinical Trial Timeline

    9.2.4 High Cost for Research and Development

10. Global Bispecific Antibody Market Future Prospects

11. Global Bispecific Antibodies Clinical Pipeline by Company, Indication and Phase

  11.1 Research

  11.2 Preclinical

  11.3 Phase-I

  11.4 Phase-I/II

  11.5 Phase-II

  11.6 Phase-III

12. Marketed Global Bispecific Antibodies Clinical Insight by Company and Indication

  12.1 Emicizumab (HEMLIBRA)

  12.2 Blinatumomab (Blincyto)

13. No Development Reported and Discontinued Global Bispecific Antibodies Clinical Pipeline by Company, Indication and Phase

  13.1 No Development Reported

  13.2 Discontinued

  13.3 Market Withdrawal

14. Competitive Landscape

  14.1 Ablynx

  14.2 Adimab

  14.3 Affimed Therapeutics

  14.4 Amgen

  14.5 AstraZeneca (MedImmune)

  14.6 Chugai Pharmaceutical

  14.7 Eli Lilly

  14.8 EMD Serono

  14.9 Emergent BioSolutions

  14.10 Genentech

  14.11 Genmab

  14.12 Immunomedics

  14.13 Jounce Therapeutics

  14.14 MacroGenics

  14.15 Merus

  14.16 Neovii Biotech

  14.17 NovImmune SA

  14.18 OncoMed Pharmaceuticals

  14.19 Pieris

  14.20 Regeneron Pharmaceuticals

  14.21 Roche

  14.22 Sanofi